Molecular BCR::ABL1 Quantification and ABL1 Mutation Detection as Essential Tools for the Clinical Management of Chronic Myeloid Leukemia Patients: Results from a Brazilian Single-Center Study

• Published in: International journal of molecular sciences Vol. 24; no. 12; p. 10118
• Main Authors: Marin, Anelis Maria, Wosniaki, Denise Kusma, Sanchuki, Heloisa Bruna Soligo, Munhoz, Eduardo Cilião, Nardin, Jeanine Marie, Soares, Gabriela Silva, Espinace, Dhienifer Caroline, de Holanda Farias, João Samuel, Veroneze, Bruna, Becker, Luiz Felipe, Costa, Guilherme Lima, Beltrame, Olair Carlos, de Oliveira, Jaqueline Carvalho, Cambri, Geison, Zanette, Dalila Luciola, Aoki, Mateus Nóbrega
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 14-06-2023; MDPI
• Subjects: Abl1 gene; ABL1 mutation; BCR protein; BCR::ABL1; Bone marrow; Brazil; Cancer; Chronic myeloid leukemia; Drug Resistance, Neoplasm - genetics; Enzymes; Fusion Proteins, bcr-abl - genetics; Guidelines; Health services; Humans; Kinases; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Molecular biology; Mutation; Myeloid leukemia; Patients; Phosphorylation; prognostic; Protein Kinase Inhibitors - pharmacology; Protein transport; Protein-tyrosine kinase; Response rates; Stem cell transplantation; TKI; Translocation, Genetic; Tyrosine; Brazil; prognostic; ABL1 mutation; chronic myeloid leukemia; TKI; BCR::ABL1
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms241210118

Chronic myeloid leukemia (CML) is a well-characterized oncological disease in which virtually all patients possess a translocation (9;22) that generates the tyrosine kinase
protein. This translocation represents one of the milestones in molecular oncology in terms of both diagnostic and prognostic evaluations. The molecular detection of the
transcription is a required factor for CML diagnosis, and its molecular quantification is essential for assessing treatment options and clinical approaches. In the CML molecular context, point mutations on the
gene are also a challenge for clinical guidelines because several mutations are responsible for tyrosine kinase inhibitor resistance, indicating that a change may be necessary in the treatment protocol. So far, the European LeukemiaNet and the National Comprehensive Cancer Network (NCCN) have presented international guidelines on CML molecular approaches, especially those related to
expression. In this study, we show almost three years' worth of data regarding the clinical treatment of CML patients at the Erasto Gaertner Hospital, Curitiba, Brazil. These data primarily comprise 155 patients and 532 clinical samples.
quantification by a duplex-one-step RT-qPCR and
mutations detection were conducted. Furthermore, digital PCR for both
expression and
mutations were conducted in a sub-cohort. This manuscript describes and discusses the clinical importance and relevance of molecular biology testing in Brazilian CML patients, demonstrating its cost-effectiveness.